N Trystram et al. Alimentary Pharmacology & Therapeutics, 01 Mar 2021, 53(8):887-899 Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Key findings:
- Drug persistence was high (94.9%) after 54 weeks in cohort of 158 patients
- Double switching from the originator Infliximab to CT-P13 and then to SB2 was associated with continued effectiveness; this study did not identify issues related to immunogenicity or safety of anti-TNF therapy after 54 weeks of follow-up.
My take: There is very limited data on repeated infliximab product changes; this small study did not identify any problems. Due to mandates from insurance, more frequent switching is likely to be more widespread and more definitive outcome data will emerge.
Abstract:
Related blog posts:
- ESPGHAN Position Paper on Biosimilars
- Big Biosimilar Study
- Interchangeability, Immunogenecity and Infliximab Biosimilars
- Biosimilars: “The Horse is out of the barn”
- Pediatric Views on Biosimilars and Interchangeability
- Role of Biosimilars in Inflammatory Bowel Disease | gutsandgrowthEuropean Experience with Biosimilars
- Biosimilars -Position Statement
gutsandgrowth 